SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
SKBI was delisted on the 18th of December, 2015.
15 hedge funds and large institutions have $1.4M invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
41% less capital invested
Capital invested by funds: $2.38M → $1.4M (-$986K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$90.9K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$67.9K |
| 3 |
Morgan Stanley
New York
|
+$14.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$11.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$340K |
| 2 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$70K |
| 3 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$38.6K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$20K |
| 5 |
SIM
Spark Investment Management
New York
|
-$6.85K |
SKBI Hedge Fund Activity: Q2 2015 in Review
15 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q2 2015, worth a combined $1.4M — down 41% from $2.38M a quarter earlier.
Fund positioning in SKBI was balanced in Q2 2015: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $90.9K. The largest seller was Sabby Management, cutting an estimated $340K.
- 15 institutional investors held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $1.4M of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q2 2015, down 41% quarter-over-quarter.
- 3 funds opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q2 2015 and 3 closed out, a net change of 0 holders.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) buyer in Q2 2015 was Renaissance Technologies, an estimated $90.9K added.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q2 2015 was Sabby Management, an estimated $340K sold.
Based on aggregated 13F filings for Q2 2015.